An in vitro and in vivo disconnect uncovered through high-throughput identification of botulinum neurotoxin A antagonists
- 20 February 2007
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences of the United States of America
- Vol. 104 (8), 2602-2607
- https://doi.org/10.1073/pnas.0611213104
Abstract
Among the agents classified as “Category A” by the U.S. Centers for Disease Control and Prevention, botulinum neurotoxin (BoNT) is the most toxic protein known, with microgram quantities of the protein causing severe morbidity and mortality by oral or i.v. routes. Given that this toxin easily could be used in a potential bioterrorist attack, countermeasures urgently are needed to counteract the pathophysiology of BoNT. At a molecular level, BoNT exerts its paralytic effects through intracellular cleavage of vesicle docking proteins and subsequent organism-wide autonomic dysfunction. In an effort to identify small molecules that would disrupt the interaction between the light-chain metalloprotease of BoNT serotype A and its cognate substrate, a multifaceted screening effort was undertaken. Through the combination of in vitro screening against an optimized variant of the light chain involving kinetic analysis, cellular protection assays, and in vivo mouse toxicity assays, molecules that prevent BoNT/A-induced intracellular substrate cleavage and extend the time to death of animals challenged with lethal toxin doses were identified. Significantly, the two most efficacious compounds in vivo showed less effective activity in cellular assays intended to mimic BoNT exposure; indeed, one of these compounds was cytotoxic at concentrations three orders of magnitude below its effective dose in animals. These two lead compounds have surprisingly simple molecular structures and are readily amenable to optimization efforts for improvements in their biological activity. The findings validate the use of high-throughput screening protocols to define previously unrecognized chemical scaffolds for the development of therapeutic agents to treat BoNT exposure.Keywords
This publication has 49 references indexed in Scilit:
- Inhibition of Metalloprotease Botulinum Serotype A from a Pseudo-peptide Binding Mode to a Small Molecule That Is Active in Primary NeuronsPublished by Elsevier BV ,2007
- Synthesis, Characterization and Development of a High-Throughput Methodology for the Discovery of Botulinum Neurotoxin A InhibitorsJournal of Combinatorial Chemistry, 2006
- Identification of a Potent Botulinum Neurotoxin A Protease Inhibitor Using in Situ Lead Identification ChemistryOrganic Letters, 2006
- Human Botulism Immune Globulin for the Treatment of Infant BotulismNew England Journal of Medicine, 2006
- Discovery of Acetylcholinesterase Peripheral Anionic Site Ligands through Computational Refinement of a Directed LibraryBiochemistry, 2005
- Vitamin B2‐mediated cellular photoinhibition of botulinum neurotoxin AFEBS Letters, 2005
- Botulinum Neurotoxin A Activity Is Dependent upon the Presence of Specific Gangliosides in Neuroblastoma Cells Expressing Synaptotagmin IPublished by Elsevier BV ,2002
- The atomic structure of protein-protein recognition sites 1 1Edited by A. R. FershtJournal of Molecular Biology, 1999
- Anatomy of hot spots in protein interfacesJournal of Molecular Biology, 1998
- Shape Complementarity at Protein/Protein InterfacesJournal of Molecular Biology, 1993